Status:
ACTIVE_NOT_RECRUITING
Dexmedtomodine Effect on Agitated Psychotic Patients Suffer COPD
Lead Sponsor:
Tanta University
Collaborating Sponsors:
Laila Ahmed Abd-Elmotaleb El-Ahwal
Marwa Ahmed Abogabal
Conditions:
Response of Agitated Patients to Dexmedetomidine
Eligibility:
All Genders
18-60 years
Brief Summary
Many studies approved dexmedetomodine as a drug controlled agitation for psychotic patients and also for patients on non invasive ventilation. So we study the same effect on agitated patients who are...
Detailed Description
Chronic obstructive pulmonary disease (COPD) characterized by progressive airflow limitation and tissue destruction as there are structural lung changes due to chronic inflammation from prolonged expo...
Eligibility Criteria
Inclusion
- Patients aged 18 - 60 years, ASA III (agitated and exacerbated COPD patients).
Exclusion
- Patients with GCS \< 8 (need invasive ventilation).
- Failure of non-invasive ventilation.
- Patients with fascial trauma or surgery.
- Patients with esophageal varices.
- Patients with recent GIT surgeries.
Key Trial Info
Start Date :
June 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 10 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06567587
Start Date
June 10 2024
End Date
March 10 2025
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta
Tanta, Tanta, Egypt, 0020